A recent study demonstrated PTPN13 involvement in cisplatin sensitivity of HNSCC cell lines (WSU-HN6 and CAL-27) where cancer-derived IgG inhibition upregulates PTPN13, resulting in the inhibition of the SRC/PKD1/AKT pathway [133]. Here, PTPN13 is linked to head and neck squamous cell carcinoma.